O
RPRX icon

Ossiam’s Royalty Pharma RPRX Stock Holding History

Ossiam’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Buy
304,236
+298,223
+4,960% +$15.5M 0.23% 71
2026
Q1 		$288K Buy
6,013
+475
+9% +$20.8K 0.01% 315
2025
Q4 		$214K Sell
5,538
-3,513
-39% -$134K ﹤0.01% 329
2025
Q3 		$319K Sell
9,051
-1,476
-14% -$53.4K ﹤0.01% 585
2025
Q2 		$379K Hold
10,527
– – ﹤0.01% 495
2025
Q1 		$328K Sell
10,527
-3,716
-26% -$118K ﹤0.01% 466
2024
Q4 		$363K Buy
14,243
+6,268
+79% +$166K 0.01% 490
2024
Q3 		$226K Buy
7,975
+1,049
+15% +$29.1K ﹤0.01% 528
2024
Q2 		$183K Buy
6,926
+238
+4% +$6.6K ﹤0.01% 540
2024
Q1 		$203K Sell
6,688
-5,084
-43% -$150K ﹤0.01% 567
2023
Q4 		$331K Hold
11,772
– – 0.01% 541
2023
Q3 		$319K Buy
11,772
+5,111
+77% +$152K 0.01% 551
2023
Q2 		$205K Buy
6,661
+3,000
+82% +$102K ﹤0.01% 615
2023
Q1 		$132K Buy
3,661
+668
+22% +$24.8K ﹤0.01% 552
2022
Q4 		$118K Hold
2,993
– – ﹤0.01% 549
2022
Q3 		$120K Buy
+2,993
New +$128K ﹤0.01% 528

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ossiam's RPRX Position: Q2 2026 in Review

Ossiam increased its Royalty Pharma (RPRX) stake by 4,960% in Q2 2026, buying an estimated $15.5M and bringing the position to 304,236 shares worth $17.1M. The position accounts for 0.23% of the portfolio, ranked #71.

Ossiam first reported a position in RPRX in Q3 2022 and has held it in 16 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Ossiam held 304,236 shares of Royalty Pharma worth $17.1M as of Q2 2026.
  • Ossiam bought 298,223 Royalty Pharma shares in Q2 2026, an estimated $15.5M.
  • Royalty Pharma made up 0.23% of Ossiam's portfolio in Q2 2026, its #71 holding.
  • Ossiam first reported a position in Royalty Pharma in Q3 2022 and has held it in 16 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Ossiam's 13F filing for Q2 2026, filed 13 Aug 2026.